North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market

Market Introduction

North America market has been segmented into the US, Canada, and Mexico. The US dominated the North America market in 2020. The market's growth is primarily attributed to the increasing prevalence of conditions such as immunodeficiency syndromes and pancreatic exocrine insufficiency amongst others. Growing prevalence of risk factors associated with the SIBO are also expected to drive the prevalence of the condition, which will eventually offer favorable environment for growth of US small intestinal bacterial overgrowth diagnostics market by 2027. For instance, according to a study published by group of researchers at Northwell Health System, Division of Gastroenterology, New York in 2017, obesity is one of the prominent causes and risk factors to drive the bacterial overgrowth in small intestine. Small intestinal bacterial overgrowth (SIBO) has been incorporated with anatomical and motility-related abnormalities. Mainly, obesity has been proposed to change small bowel motility, leading to SIBO. As a result, SIBO was more frequent amongst obese patients vs. non-obese patients (88.9% vs. 42.9%). Obese vs. non-obese patients presented notable differences in microbiome diversity in rectal samples. Obesity was connected with increased odds of developing SIBO. Therefore, rising prevalence of obesity will ultimately offer a lucrative opportunity for growth of the market. Growing prevalence of IBS and SIBO and increasing advantages of breath test are the major factor driving the growth of the North America small intestinal bacterial overgrowth (SIBO) diagnostics market.

In case of COVID-19, North America is highly affected specially the US. Industrial sectors in the countries such as the US and Canada has experienced disruption in various industries, including healthcare. However, the need for diagnosis and treatment for the COVID positive patients has carried on business cycles in the medical sector. In addition, the rising demand for personal protective equipment has tried to stabilize the business cycle for the healthcare industry. According to an article issued by Harvard Medical School, infectious viral particles can live in the air for three hours. As a result, it can cause patient scheduling obstructions and put others at risk for contracting the virus. For healthcare providers demanding to test for GI-related problems offered by patients, a substitute for in-office breath testing must be granted due to the potential spread of COVID-19 through aerosolization. Unfortunately, the possible aerosolization spread of COVID-19 makes breath testing in-office comparatively unsafe and has been in a bit of a dilemma in the clinic during this pandemic. The small intestinal bacterial overgrowth diagnostics market also witnessed major decline due to lowered number of diagnostic procedures. Substantial focus on management of COVID had direct impact on diagnostics of abdominal conditions such as irritable bowel syndrome, SIBO, and lactose intolerance. In addition, patients showed reluctance for breath and blood tests due to fear of COVID infection. These factors consequently led to adverse impact on North America small intestinal bacterial overgrowth market during the pandemic period. However, the market is expected to witness considerable growth post-pandemic. Certain factors such as rise in prevalence of SIBO and IBS are estimated to show positive impact on market growth.

Market Overview and Dynamics

The North America small intestinal bacterial overgrowth (SIBO) diagnostics market is expected to grow from US$ 53,452.06 thousand in 2021 to US$ 73,794.03 thousand by 2028; it is estimated to grow at a CAGR of 4.7% from 2021 to 2028. There has been a constant development in SIBO diagnostics. The currently used breath test has low sensitivity and specificity. Therefore, the additional validation studies are undergoing to define standard protocols. The growing technological developments in the field of medical devices have offered various innovative products to diagnose several complex human health conditions. Thus, to diagnose SIBO, an innovative orally ingested capsule technology is in the developmental process. It is designed in a way to measure in vivo hydrogen and carbon-di-oxide after ingestion of a carbohydrate meal and provide a technologically updated alternative to the current breath hydrogen test. It is expected that the capsule technology will help in diagnosing samples of small bowel bacteria. Thus, the introduction of capsule technology is likely to emerge in the coming future and contribute to direct and accurate evaluation of SIBO and offer vital growth opportunities for the North America market’s growth.

Key Market Segments

In terms of diagnosis, the breath testing segment accounted for the largest share of the North America small intestinal bacterial overgrowth (SIBO) diagnostics market in 2020. In terms of type, the hydrogen-predominant SIBO segment held a larger market share of the North America small intestinal bacterial overgrowth (SIBO) diagnostics market in 2020.     

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the North America small intestinal bacterial overgrowth (SIBO) diagnostics market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Aerodiagnostics, LLC.; Commonwealth Diagnostics International; DirectLabs, LLC.; Genova Diagnostics; Health Associates Medical Group; Metabolic Solutions, Inc.; Pivotal Diagnostics; SIBO Diagnostics; SIBOTest; and Vibrant Wellness.

Reasons to buy report

• To understand the North America small intestinal bacterial overgrowth (SIBO) diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for North America small intestinal bacterial overgrowth (SIBO) diagnostics market
• Efficiently plan M&A and partnership deals in North America small intestinal bacterial overgrowth (SIBO) diagnostics market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America small intestinal bacterial overgrowth (SIBO) diagnostics market
• Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Segmentation 

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market – By Diagonisis

• Breath Testing
  • 14C Xylose Breath Test
  • Hydrogen Breath Tests
  • 14C Glycocholic Acid Breath Test
  • Malabsorption Tests
• Small Intestine Aspirate and Fluid Culture Test
• Blood Test
• Others

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market – By Type

• Hydrogen-predominant SIBO
• Methane-predominant SIBO
• Recurrent SIBO

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market , By Country

• US
• Canada
• Mexico

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market - Company Profiles

• Aerodiagnostics, LLC.     
• Commonwealth Diagnostics International
• DirectLabs, LLC.
• Genova Diagnostics
• Health Associates Medical Group
• Metabolic Solutions, Inc.
• Pivotal Diagnostics
• SIBO Diagnostics
• SIBOTest
• Vibrant Wellness

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Strategic Insights

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Segmentation Analysis

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Report Highlights

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Report Scope

North America Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Country and Regional Insights